This is a news story, published by UC San Diego Health, that relates primarily to the New England Journal of Medicine news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from UC San Diego Health, you can click here:
more news from UC San Diego HealthOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
OSA patients. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest sleep apnea news, sleep medicine news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
common sleep apnea treatmentUC San Diego Health
•
86% Informative
The number of OSA patients worldwide is close to 936 million .
Tirzepatide, known to manage type 2 diabetes, is the first effective drug therapy for obstructive sleep apnea.
The most common side effect reported was mild stomach issues.
The results were published in the June 21, 2024 online edition of the New England Journal of Medicine .
VR Score
90
Informative language
94
Neutral language
37
Article tone
formal
Language
English
Language complexity
75
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
2
Source diversity
2
Affiliate links
no affiliate links